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devices that can make these new techniques feasible.2
Important advances were observed, not only in the tech-
nology itself but also in strategies and care pathways, in pa-
tients with CD undergoing surgery. This can be represented 
by the development of enhanced recovery protocols and the 
individualized definition of the proper timing for the surgi-
cal procedure, mainly based on the relation of surgical out-
comes with perioperative medical therapy, mostly after the 
biological era.3,4
Currently, abdominal surgery is indicated for CD; how-
ever, a considerable number of patients have previous expo-
sure to biological therapy, and there is still controversy about 
INTRODUCTION
In the management of CD, different therapeutic strategies 
aimed at disease control are available. During the last two 
decades, significant advances in medical therapy, mainly 
based on clinical experiences with biological agents, were 
achieved.1 These new agents also contributed to reducing 
the surgical rates; however, surgery is still needed in a signifi-
cant proportion of patients. The surgical therapy for CD has 
also evolved, mainly owing to the growing expertise in mini-
mally invasive techniques, such as multiport and single-port 
laparoscopy, and the development of innovative surgical 
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Recent advances in medical and surgical therapy were achieved during the last two decades in the management of Crohn’s 
disease (CD). Anti-tumor necrosis factor (anti-TNF) agents are widely used worldwide. However, a significant proportion of 
patients still need surgical resections. The impact of previous exposure to these agents on the perioperative and postoperative 
outcomes is still controversial. In this critical review, we aimed to position the strategy of intentional preoperative use of anti-
TNF agents in the management of CD. The indications and contraindications for this strategy are detailed, and despite scarce 
evidence, the possible advantages and disadvantages of the intentional use of anti-TNF agents before abdominal surgery in CD 
are discussed. (Intest Res 2017;15:160-165)
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whether anti-tumor necrosis factor (anti-TNF) therapy in the 
preoperative period could be a risk factor for both infectious 
and surgical complications in these patients. Different stud-
ies and meta-analyses revealed opposite conclusions, with 
limited but similar methodological issues.5,6 Two prospective 
cohort studies reported that there can be an increase in post-
operative complications after abdominal surgery for CD in 
patients previously exposed to infliximab (IFX).7,8 In one of 
these studies, Lau et al.7 described that higher serum levels 
of the drug in the preoperative period (≥8 µg/mL) were as-
sociated with higher readmission and overall complication 
rates. More prospective data in this field are needed.
Indeed, CD can be heterogeneous, and several pheno-
types of the disease can be observed concurrently in clinical 
practice. Frequently, patients with an established surgical 
indication for stenosis or internal fistula, for instance, may 
present with a high inflammatory burden associated to lumi-
nal CD or mesenteric masses without abscesses, and need 
a decrease in their inflammatory status to be optimized for 
surgery.
The strategy of intentional preoperative anti-TNF therapy 
in CD is attractive, and may be part of the real-life practice 
for severe cases of CD worldwide. In the management of rec-
tal cancer, neoadjuvant therapy leads to a reduction in the 
tumor size, with postponed surgery having better outcomes. 
There is a controversy whether a similar principle could be 
applied in the management of specific complicated cases of 
abdominal CD. The question arises whether patients with an 
established surgical indication, with inflammatory masses, 
and without infection would receive any benefit from reduc-
ing the inflammatory burden with a fast-acting treatment 
with anti-TNF therapy. Whether the surgical procedure 
would be facilitated, with the advantages of reduced bleed-
ing, more economic resections, and reduced operative time, 
still needs to be proven with specific studies. On the con-
trary, there is the obvious concern about the safety of anti-
TNF agents in the perioperative period, as previously stated.
The aim of this critical review was to analyze the possible 
indications, contraindications, and consequences of the in-
tentional use of preoperative anti-TNF therapy in abdominal 
CD, and to outline the potential variables involved in this 
strategy.
POSSIBLE INDICATIONS FOR INTENTIONAL 
PREOPERATIVE ANTI-TNF THERAPY
Patients with a high inflammatory burden and clear sur-
gical indication could possibly benefit from the strategy of 
preoperative anti-TNF agents. This would include patients 
with inflammatory masses in the mesentery or mesocolon, 
without abscesses or phlegmons, and with associated fibrot-
ic stenosis or internal fistulas. It is known that patients can 
present different phenotypes of the disease simultaneously. 
A typical example is the occurrence of an ileal fibrotic steno-
sis, with proximal dilatation, associated ileitis, and an ileo-
sigmoid fistula. In the same scenario, patients with luminal, 
stenosing, and penetrating disease, with a clear indication 
for a surgical procedure, could possibly benefit from a reduc-
tion in inflammation with biological agents.
Another possible indication of this strategy is extensive 
luminal small bowel disease, with specific localized fibrotic 
stenosis in certain parts of the jejunum and ileum. Preopera-
tive medication could theoretically reduce the inflammatory 
lesions, leading to mucosal healing, with surgery being indi-
cated as a complementary approach in the fibrotic stenotic 
areas, with resection or strictureplasty. A third possible 
indication could be pancolitis associated with CD, in which 
preoperative anti-TNF could heal parts of the mucosa in de-
termined segments of the large bowel, leading to a change in 
the surgical indication from a total colectomy to segmental 
colectomies. Likewise, rectal preservation could be aimed 
in patients with rectal mucosal healing due to anti-TNF ther-
apy. This can preserve the rectum after the administration 
of biologics, in fibrotic colons with complete loss of haustra-
tions, and impaired absorption and reservoir function, with 
ileorectal anastomosis being performed instead of total 
proctocolectomies. In these cases, previous anti-TNF agents 
could prevent permanent stomas with preservation of the 
rectum—certainly a more attractive option to patients—
when properly indicated. In all previously discussed situa-
tions (detailed in Table 1), active infection must be excluded.
CONTRAINDICATIONS FOR INTENTIONAL 
PREOPERATIVE ANTI-TNF THERAPY
Some patients have absolute contraindications for the 
strategy of intentional use of anti-TNFs before surgery.9 This 
would obviously include those with concomitant intra- or 
extra-abdominal infections at the time of the surgical indica-
tion. Patients with single or multiple abdominal abscesses 
would also be included in this group. Moreover, patients with 
associated systemic infections such as pneumonia, urinary 
tract infections, or sepsis from any other source clearly are 
not candidates for this strategy, owing to the significant risk 
of immunosuppression in this specific population.
Patients with contraindications for the use of anti-TNFs 
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in general also cannot benefit from this strategy, and this in-
cludes patients with demyelinating disease (multiple sclero-
sis, multifocal motor neuropathy) and those with American 
Heart Association grades III and IV heart failure.9
Patients with a clear indication for emergency surgery 
also have contraindications to the preoperative anti-TNF 
strategy, as the time needed for a response is not available in 
this situation.10 This would include patients with blocked or 
free perforations in any bowel segment, as well as patients 
with acute bowel obstruction. These patients need immedi-
ate surgical therapy, and cannot be ideally optimized for the 
previously discussed preoperative strategy (Table 2).
PROMISING THEORETICAL ADVANTAGES 
OF INTENTIONAL PREOPERATIVE ANTI-TNF 
THERAPY
From the surgical perspective, a reduction in an inflam-
matory mesenteric mass could lead to a less complicated 
procedure. Usually, the thickened mesentery in CD can 
be challenging to deal with, and hemostasis often needs 
achievement of continuous needle suturing owing to consid-
erable tissue friability. Moreover, local edema can also lead 
to increased surgical time due to technical difficulties and 
bleeding. Operating tissues in a better condition (with less 
inflammation) could be a consequence of the intentional 
preoperative anti-TNF strategy. 
A reduction in the inflammatory burden could also 
change the approach of the procedure. Commonly, large 
inflammatory masses with associated external or internal 
fistulas are primarily treated with an open approach with 
longer incisions and more significant surgical trauma, the 
consequences of which can influence the postoperative re-
covery. A reduction in the size of the specimen, including the 
resected bowel and mesentery, could also make a minimally 
invasive procedure feasible, and this could be another surgi-
cal benefit of preoperative anti-TNFs. Moreover, increased 
reduction in the complexity of the procedure may possibly 
lower the need for blood transfusions—a known risk factor 
for a more complicated postoperative period.
From the clinician’s perspective, several benefits could be 
aimed. First, preoperative anti-TNF with consequent reduc-
tion of the inflammatory burden could optimize the patients’ 
status for surgery. This could result in an improvement in 
nutrition and compensation for anemia, which could de-
crease the postoperative complication rates. Another im-
portant point is the possibility of more economic resections, 
reducing the chances of intestinal failure in the long term, 
mainly in patients with previous resections. Although there 
is lack of evidence on this topic, a reduction in inflammation 
could limit the resections, mainly in the small bowel, and a 
negative nutritional impact in the postoperative follow-up 
could be possibly avoided. Preservation of the rectum can 
also be a potential advantage from the clinical point of view, 
Table 1. Main Theoretical Objectives and Indications of Intentional Preoperative Use of Anti-TNF Agents
Possible arguments for intentional preoperative anti-TNF therapy in CD
1. Reduction of inflammatory masses aiming more economic small bowel resections
2. Reduction of inflammation in extensive small bowel disease before strictureplasties or segmental resections
3. Reduction of colonic inflammation that can lead to segmental instead of total colectomies in Crohn’s colitis
4. Rectal preservation in patients with chronic refractory colitis with lead pipe colon after rectal mucosal healing, avoiding permanent stomas
5.  Optimizing the patient’s condition for surgery (reduction of inflammatory burden and improvement in nutritional status through reduction in 
disease activity)
TNF, tumor necrosis factor.
Table 2. Contraindications for Preoperative Anti-TNF Therapy Owing to Safety Issues
Contraindications for deliberative preoperative anti-TNF therapy in CD
1. Associated abdominal abscess to CD (abdominal infections)
2. Extra-abdominal concomitant infections (pneumonia, urinary tract infection, etc.)
3. Contraindications for anti-TNF therapy per se (demyelinating diseases, heart failure)
4. Emergency situations (bowel perforations, acute or subacute obstructions in the small or large bowel)
TNF, tumor necrosis factor.
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as a better bowel function can be observed after surgery in 
cases with ileorectal anastomosis. Stoma avoidance could 
also be an advantage, as the presence of a stoma has psycho-
logical effects on and difficult to accept for patients, in addi-
tion to requiring specialized care.
Coscia et al.11 described the profile of surgical therapy for 
colonic CD before and after the biological era. In their retro-
spective cohort study from Italy, the authors showed that the 
rate of permanent stomas was 60.8% in the prebiological era 
and 19.2% after this period, when biologics were widely used 
(P <0.001). Moreover, univariate and multivariate analyses 
showed that only the use of biologics was significantly asso-
ciated with an increased rate of rectal preservation in those 
patients (P<0.05). The preoperative use of anti-TNF agents in 
these patients did not have an intentional protocol; however, 
it showed the capacity for rectal preservation possibly owing 
to mucosal healing caused by the biological agents, which 
possibly influenced the long-term surgical outcomes.
de Groof et al.,12 in an interesting study from the Neth-
erlands, compared the length of specimens from ileocolic 
resections between patients from a population-based cohort 
and patients from a referral center who had more intensive 
medical therapy. When grouped according to anti-TNF use, 
a median length of resected ileum of 21.0 cm (IQR, 12.5–
33.5) was observed in patients with previous anti-TNF as 
compared with 20.0 cm (IQR, 12.0–30.0) in patients without 
anti-TNF treatment (P =0.87). Patients treated with a more 
intensive therapy, such as biologics, had a significant delay in 
the surgical indication from the diagnosis to the first ileocolic 
resection. This retrospective analysis suggests that the use 
of anti-TNF agents before surgery still did not result in a re-
duction in the length of specimens after ileocolic resection, 
which demonstrates the controversy about the real impact 
of biologics in bowel sparing.
PERIOPERATIVE ANTI-TNF AND COMPLICATIONS: 
CURRENT EVIDENCE AND POSSIBLE PITFALLS
The literature shows that the impact of anti-TNF agents 
on postoperative outcomes is largely controversial. Several 
meta-analyses demonstrated different results.5,6 In the same 
way, animal experimental studies were performed and dem-
onstrated opposite results.13,14
There are several case series describing the impact of 
preoperative anti-TNF agents on postoperative outcomes 
after abdominal procedures in CD. A more detailed analy-
sis of these previous reports shows some differences in the 
methodology used among studies. Some studies included 
patients with CD and those with UC in the same sample.15,16 
The outcomes analyzed were also different among the stud-
ies. Some exclusively analyzed surgical complications, others 
infectious complications, and some postoperative compli-
cations in general.5,6,15,16 The heterogeneity of these results 
demonstrates the controversy about the consequences of bi-
ological therapy in surgical patients with CD, and this needs 
to be taken into account if the intentional preoperative anti-
TNF strategy is aimed.
Only two prospective studies have analyzed the relation 
between preoperative exposure to anti-TNF therapy and sur-
gical complications in CD. Lau et al.7 analyzed 123 patients 
in whom serum levels of IFX were measured 7 days before 
the surgical procedure. More overall postoperative compli-
cations and more readmissions were observed in patients 
with IFX levels >8 µg/mL than in those with levels <3 µg/mL. 
This difference was only observed in patients with CD, not 
after surgical procedures in patients with UC. The authors 
suggested that circulating anti-TNF agents may have an in-
fluence on surgical complications.
 Similar results were observed in a prospective multicenter 
French study (RICCO registry), presented at the European 
Crohn’s and Colitis Organisation Congress, 2016.8 From a 
total of 592 patients submitted exclusively to ileocecal resec-
tions for CD, 23.1% received previous anti-TNF therapy up to 
6 months before surgery. There were higher rates of overall 
morbidity (41% vs. 26%, P =0.001) and abdominal sepsis 
(13% vs. 7.1%, P =0.030) in the group of patients with previ-
ous anti-TNF than in controls. The use of anti-TNF agents 
<6 months before surgery remained a strong predictor of 
overall postoperative morbidity (OR, 2.10; 95% CI, 1.60–2.75; 
P <0.0001) and intra-abdominal sepsis (OR, 3.13; 95% CI, 
2.07–4.73; P <0.001). The results of this trial were not based 
on serum levels. Moreover, as it included patients with ex-
posure to anti-TNF agents up to 6 months before the opera-
tions, some patients even could not have any circulating anti-
TNF agents during the procedures. This raises the question 
of whether the anti-TNF agent per se was the direct cause 
of more complications, or if a coincidental profile and more 
complicated patients were included in the analysis.
Therefore, more prospective comparative data aiming to 
analyze the effect of preoperative anti-TNF therapy on post-
operative surgical outcomes in CD are needed. It has been 
clearly demonstrated that preoperative steroids and malnu-
trition increase the complication rates after surgery in CD.10 
Usually, sicker patients are treated with biological agents, 
and this can be the confounding factor resulting in increased 
postoperative complications in some studies. 
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As most of the retrospective studies tend to show a lack 
of influence of these agents on postoperative complica-
tions, several referral IBD centers do not routinely interrupt 
therapy in patients with CD undergoing elective abdominal 
surgery, which can lead to the rationale of the intentional 
preoperative strategy described in this critical review. Pitfalls 
such as preoperative steroid use and malnutrition are also 
important in this individualized decision.
Usually, biological agents need some time before they ex-
ert their full action, and thus before the treatment response 
can be evaluated. The induction period varies depending 
on the agent (usually 4 weeks for adalimumab and certoli-
zumab pegol, and 14 weeks for IFX). However, there is ex-
pert consensus that at least 12 weeks are needed for patients 
to acquire the benefit of reduced inflammatory burden. 
Clearly, infections could occur in this intermediate period 
(between the first dose of the anti-TNF agent and surgery), 
based on the previous wide experience with all anti-TNF 
agents. Therefore, close monitoring is recommended if the 
intentional preoperative anti-TNF strategy is performed.
Another potential disadvantage of using anti-TNFs inten-
tionally is the obvious significant increase in the therapy 
costs.17 Even with the possibility of reduced surgical time and 
hospital stay, pharmacoeconomic studies would be needed 
to better clarify the cost-benefit ratio of this strategy. The 
potential theoretical advantages and disadvantages of inten-
tional preoperative use of anti-TNF agents are described in 
Fig. 1.
FINAL MESSAGES AND CONCLUSIONS
Deliberative use of preoperative anti-TNF therapy in pa-
tients with CD can be challenging and it requires more re-
search for implementation in clinical practice. The potential 
benefits need to be specifically balanced against the possible 
risks of increasing postoperative complication rates, as there 
is controversy in the literature about whether anti-TNF treat-
ment worsens outcomes because of the agents per se or as 
a coincidental factor related to the more severe disease of 
patients. Thus, the decision to intentionally administer anti-
TNF before surgery must be individualized and be made by 
a multidisciplinary team, including surgeons and gastroen-
terologists, to optimize the outcomes in patients specifically 
selected for this strategy. Further studies are urgently needed. 
However, in the meantime, the authors believe that on the 
balance of evidence, there is a place for intentional preopera-
tive anti-TNF therapy in very carefully selected patients.
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